White House Withdraws FDA Commissioner Nominee as Senator Roger Marshall Emerges as Possible Replacement
Key Points
- The Trump administration withdrew Heidi Overton's nomination to lead the FDA amid concerns she lacked sufficient Senate support for confirmation.
- Senator Roger Marshall (R-KS), an obstetrician-gynecologist on the Senate HELP Committee, is reportedly being considered as a possible replacement.
- The next FDA commissioner will oversee vaccine policy, drug approvals, and the administration's mifepristone safety review due by March.
The Trump administration has withdrawn its nomination of Heidi Overton to lead the U.S. Food and Drug Administration (FDA), following growing concerns that she lacked sufficient support to secure Senate confirmation. Attention is now shifting to Senator Roger Marshall (R-KS), who is reportedly being considered as a possible replacement, according to Reuters and Semafor.
Overton, a physician and White House domestic policy adviser, was nominated in August to succeed former FDA Commissioner Marty Makary. Her nomination faced scrutiny from lawmakers in both parties, particularly regarding her positions on vaccine policy, scientific independence and abortion-related issues.
Republican Senator Bill Cassidy (R-LA), chairman of the Senate Health, Education, Labor and Pensions (HELP) Committee, had expressed reservations about Overton’s willingness to maintain scientific independence from the administration. Cassidy previously criticized her support for proposals to separate combination vaccines, including the measles, mumps and rubella (MMR) vaccine.
However, Cassidy indicated following the withdrawal that he believed Overton ultimately could have secured enough votes for confirmation. He attributed the decision to disagreements between the White House and anti-abortion Republicans over commitments on abortion-related policy issues.
The nomination also encountered opposition from other Republican lawmakers, including Senator Susan Collins (R-ME), who raised concerns about Overton’s position on flavored e-cigarettes. Her nomination would have required support from all 12 Republican members of the Senate HELP Committee, which has 11 Democratic members.
Marshall, an obstetrician-gynecologist and former member of the House of Representatives, currently serves on the Senate HELP Committee. He is completing his Senate term after losing his reelection bid, and his medical background and congressional experience could make him a potential alternative for the administration.
A Trump administration official told Semafor that Marshall was viewed as an alternative if Overton could not secure confirmation, noting that sitting senators have historically had an easier path through the confirmation process.
The leadership uncertainty comes as the FDA continues to navigate several high-profile regulatory and policy issues, including vaccine oversight, drug approvals and the administration’s review of mifepristone, the medication used in medication abortion. The agency has been asked to complete a safety review of the drug by March, with potential implications for prescribing and dispensing requirements.
The change in nominee also comes amid efforts by Senate Republicans to advance presidential appointments before Democrats assume control of the chamber in January. For the pharmaceutical and biotechnology industries, the next FDA commissioner will take the helm of an agency responsible for overseeing drug development, clinical research, regulatory submissions, manufacturing quality and product safety. The selection process will therefore be closely watched by companies seeking clarity on the administration’s regulatory priorities and the agency’s future direction.
Total Page Views: 7

















